Development of serological assay for detection of Chikungunya virus infection by Ooi, Ka Beng
Faculty of Resource Science and Technology
DEVELOPMENT OF SEROLOGICAL ASSAY FOR DETECTION OF 
CHIKUNGUNYA VIRUS INFECTION
001 KA BENG 
(48675)
Bachelor of Science with Honours 
(Resource Biotechnology) 
2018
Development of serological assay for detection of Chikungunya virus infection
Ooi Ka Beng
48675
A thesis submitted in fulfilment of the requirement for the degree of 
Bachelor of Science with Honours
Supervisor: Dr. Magdline Sia Henry Sum 
(Institute of Health and Community Medicine) 
Co-supervisor: Madam Anna Andrew
(Faculty of Medicine and Health Sciences)
Resource Biotechnology
Faculty of Resource Science and Technology 




Please tick ('I) 
Final Year Project Report 
Masters
PhD
DECLARATION OF ORIGINAL WORK
This declaration is made on the ...... 
4..... day of .. 
A`!: `. ß.... 2018.
Student's Declaration
I, Ooi Ka Beng, 48675, Faculty of Resource Science and Technology hereby declare that the work 
entitled `Development of Serological Assay for Detection of Chikungunya Virus Infection' is my 
original work. I have not copied from any other students' work or from any other sources except 
where due reference or acknowledgement is made explicitly in the text, nor has any part been 
written for me by another person.
041 eý t zA *4-ý
Date submitted Ooi Ka Beng (48675)
Supervisor's Declaration: 
I, Dr. Magdline Sia Henry Sum hereby certifies that the work entitled 'Development Of Serological 
Assay For Detection Of Chikungunya Virus Infection' was prepared by the above named student, 
and was submitted to the "FACULTY" as a * partial/full fulfillment for the conferment of Bachelor 
Of Science With Honours In Resource Biotechnology, and the aforementioned work, to the best of 
my knowledge, is the said student's work.




(Dr. Magdline Sia Henry Sum)
iI 1I
I
I declare that Project/Thesis is classified as (Please tick (SO)
Q CONFIDENTIAL (Contains confidential information under the Official Secret Act 1972)* 
ORESTRICTED (Contains restricted information as specified by the organization where 
research was done)*
0 OPEN ACCESS
I declare this Project/Thesis is to be submitted to the Centre for Academic Information Services and 




I therefore duly affirm with free consent and willingly declare that this said Project/Thesis shall be 
placed officially in the Centre for Academic Information Services with the abiding interest and 
rights as follows:
" This Project/Thesis is the sole legal property of University Malaysia Sarawak (UNIMAS). 
" The Centre for Academic Information Services has the lawful right to make copies for 
the purpose of academic and research only and not for other purpose. 
" The Centre for Academic Information Services has the lawful right to digitalize the 
content for the Local Content Database. 
" The Centre for Academic Information Services has the lawful right to make copies of the 
Project/Thesis for academic exchange between Higher Learning Institute. 
" No dispute or any claim shall arise from the student itself neither third party on this 
Project/Thesis once it becomes the sole property of UNIMAS. 
" This Project/Thesis or any material, data and information related to it shall not be 
distributed, published or disclosed to any party by the student except with UNIMAS 
permission.
Student signature k, i Supervisor signature:
(9 June 2018) (9 June 2018)
Current Address: 
Fakulti Sains dan Teknologi Sumber, 
Universiti Malaysia Sarawak, 
94300 Kota Samarahan, 
Sarawak.
Notes: * If the Project/Thesis is CONFIDENTIAL or RESTRICTED, please attach together as 
annexure a letter from the organization with the period and reasons of confidentiality and 
restriction. 
[The instrument was prepared by The Centre for Academic Information Services]
II
ACKNOWLEDGEMENT 
Foremost, I would like to thank all the people who contributed to the work described in 
this thesis. I would like to express my sincere gratitude to my supervisor Dr. Magdline Sia Henry 
Sum for the constant guidance, advice, support of my study and research. Her guidance helped 
me in all the time of research and writing of this thesis. Besides my supervisor, I would like to 
thank my co-supervisor Madam Anna Andrew for the guidance, advice, patience, and imparting 
her knowledge and expertise in this study.
Last but not least, I would like to thank my beloved parents, Ooi Eng San and Tan Siew 
Mooi for supporting me spiritually, financially and words of encouragement throughout this 
project.
Furthermore, I would like to take this opportunity to thank the staffs of the Institute of 
Health and Community Medicine (IHCM), UNIMAS, post-graduate students and my lab mate 
Low Yong Chun, for their kind help, guidance and working together with me in the lab.
III
Development of serological assay for detection of Chikungunya virus infection
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ABSTRACT 
Chikungunya virus (CHIKV) is a mosquito-borne virus that infects human. The infection caused 
by CHIKV and dengue virus (DENV) share some common signs and symptoms which includes 
high fever, chills, rashes, joint and muscle pain. However, the prognosis, patient care, and 
persistent symptoms are different. The accurate identification of CHIKV is important during 
CHIKV outbreak, since dengue infection is endemic in Malaysia. To date, the diagnosis of 
CHIKV could only be done at Institute of Medical Research (IMR) and National Public Health 
Laboratory (NPHL) which are located at Peninsular Malaysia. Hence, the aim of this study is 
to develop a serological assay for the detection of CHIKV infection by the use of a recombinant 
antigen. The recombinant CHIKV E2 protein are expressed in Escherichia coli (E. coli) using 
pET SUMO expression system. The expressed protein was evaluated by SDS-PAGE and 
western blot. Then the E2 recombinant protein was purified through ProBond Purification 
System (Novex, CA, USA) and dialysed gradually in PBS. Then, ELISA are carried out by using 
the E2 recombinant protein against various serum and the sensitivity and specificity are 60.7% 
and 90% respectively.
Keywords: CHIKV, recombinant CHIKV E2 protein, ELISA, sensitivity, specificity.
ABSTRAK
Virus Chikungunya (CHIKV) adalah penyakit yang menjangkiti manusia melalui nyamuk. 
Jangkitan yang disebabkan oleh CHIKV dan denggi virus (DENV) berkongsi beberapa tanda 
biasa dan gejala termasuk demam, menggigil, ruam, sakit sendi dan otot. Walau bagaimanapun, 
prognosis, penjagaan pesakit, dan symptom berterusan adalah berbeza. Pengenalan tepat 
CHIKV adalah penting semasa wabak CHIKV, memandangkan jangkitan denggi adalah 
endemic di Malaysia,. Setakat ini, diagnosis jangkitan CHIKV hanya boleh dijalankan di Institut 
Penyelidikan Perubatan (IMR) dan Makmal -Kesihatan Awam Kebangsaan (NPHL) yang 
terletak di Semenanjung Malaysia. Oleh itu, tujuan kajian ini adalah untuk membangunkan 
assay serologi untuk mengesan jangkitan CHIKV dengan menggunakan antigen rekombinan. 
Rekombinan protein CHIKV E2 telah diekspres di dalam Escherichia coli (E. coli) dengan 
menggunakan sistem ekspresi pET SUMO. Protein yang diekspres telah dinilai dengan 
menggunakan SDS-PAGE dan Western blot. E2 rekombinan protein telah dipurifikasi dengan 
menggunakan ProBond Purification System (Novex, CA, USA) dan dialysed dengan beransur- 
ansur dalam PBS. Kemudian, ELISA dijalankan dengan menggunakan protein rekombinan E2 
terhadap pelbagai serum dan sensitivity dan spesifisiti adalah 60.7% dan 90% masing-masing. 
Kata kunci: CHIKV, rekombinan CHIKVE2 protein, ELISA, sensitivity, spesifisiti
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1.0 INTRODUCTION 
Chikungunya virus (CHIKV) is an arthropod-borne virus with major outbreaks in Africa, India, 
and South-East Asia (Power and Logue, 2007). CHIKV are transmitted by the same species of 
mosquitoes Aedes aegypti and Aedes ablopictus (Thiboutot et al., 2010). The major clinical 
symptom of CHIKV infection is febrile illness, which is clinically similar to symptoms of 
dengue virus infection (Karabatsos, 1975).
In Malaysia, molecular technique or immunofluorescence assay (IFA) are used for the 
detection of CHIKV infection. The molecular technique is used to detect the viral genome in the 
infected patient while IFA technique is used to detect the presence of antibodies against a 
specific antigen in serum. However, in Sarawak the validation of CHIKV infection can only be 
carried out through Institute for Medical Research (IMR) and National Public Health Laboratory 
(NPHL) at Peninsular Malaysia. Therefore, the identification of the infection will be delayed if 
an outbreak occurs because unlike dengue virus infection, CHIKV infection is rarely fatal and 
usually does not require close clinical supervision.
Due to the similar clinical symptoms of CHIKV infection with other virus infection such 
as dengue virus (DENY), CHIKV infection is often misdiagnosed (Morrison, 2014). Therefore, 
the ability to differentiate CHIKV infection from dengue virus infection would be important to 
have a proper control measures, particularly in areas where dengue virus infection is endemic 
or epidemic (Cho et al., 2008). Hence, serological assay for the detection of CHIKV infection 
should be available in Sarawak. Thus, the aim of this study is to develop a serological assay for 
the detection of CHIKV infection.
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Therefore, the objectives of this study are:
1. To express and purify the recombinant CHIKV E2 protein in Escherichia coli expression
system.
2. To determine the specificity and sensitivity of serological assay developed for detection of
CHIKV infection.
2
2.0 LITERATURE REVIEW 
2.1 Chikungunya Virus 
Chikungunya virus (CHIKV) belongs to the family Togaviridae and genus Alphavirus. The 
infection of CHIKV causes chikungunya fever (CHIK fever) which is a febrile illness linked 
with severe arthralgia and rash (McGill, 1995). The term `Chikungunya' is derived from 
Makonde word meaning that which bends up' that refers to the contorted posture of the infected 
patients suffering from severe joint pain (Mavalankar et al., 2008). CHIKV was first 
documented in 1952 during an epidemic outbreak in Makonde, Tanzania (Robinson, 1955). The 
transmission of CHIKV to humans are mostly through the bite of an infected Aedes mosquito. 
The transmission cycles of CHIKV includes urban cycle which is man - mosquito - man and 
sylvatic cycle animal - mosquito - man (Apandi et al., 2009). The main vector that involves in 
urban cycles are usually Aedes aegypti and Aedes albopictus and Aedes africanus, Aedes 
luteocephalus, Aedes furcifer and Aedes taylori are the major vector involves in sylvatic cycle 
(Thiboutot et al., 2010).
2.2 Genome of CHIKV 
The genome of CHIKV (Figure 2.1) is a linear, single stranded, positive-sense RNA virus with 
approximately 11.8 kb and is capped in 5' and polyA tail in 3' end. The genome includes two 
open reading frames (ORFs) and encodes 4 non-structural proteins (nsP1, nsP2, nsP3 and nsP4) 
and five structural proteins (Capsid, E3, E2, 6k and El) (Strauss et al., 1991). The structural 
protein E 1 and E2 associate as trimers of heterodimers (E2 - E 1) as spikes on viral surface (Voss 
et al., 2010) and the protein cover the viral surface in the form of membrane-anchored types 
(Cho et al., 2008). The viral spikes help the attachment of the virus to cell surfaces and viral 
entry into the cells. The phylogenetic trees of CHIKV (Figure 2.2) shows that there are three
3
different genotypes based on geographical origins which are ECSA (East/Central/South 
African), West Africa, and Asian (Presti et al., 2014). According to Schuffenecker et al. (2006), 
the single point mutation of alanine to valine at position 226 in E 1 envelope glycoprotein (E 1 - 
A226V 1) during the Indian Ocean outbreak enhanced the ability of CHIKV replication in 
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2.3 E2 protein of CHIKV 
E2 envelope protein in alphavirus which is a type I transmembrane glycoprotein is responsible 
for the receptor binding (Kielian and Rey, 2006; Brehin et al., 2008). E2 protein consists of three 
domains A, B and C. Domain C is situated close to the membrane of virus, domain A are 
positioned in the center of the protein and domain B are at the distal end, which prominently 
visible on the surface of the virus (Voss et al., 2010; Li et al., 2010). Domain A and B contain 
most of the residues that affect cell attachment and cell tropism (Voss et al., 2010). Based on 
the study of Weger-Lucarelli et al. (2016), the changed in domains A or C results in attenuated 
of the viruses, hence this showed that each of the domains of E2 protein have an important role 
in viral infection. Thus, E2 protein of CHIKV have been a target for recombinant subunit 
vaccine development and IgM or IgG based diagnostic assay (Verma et al., 2016).
2.4 Epidemiology of CHIKV 
CHIKV are probably originated from Central/East Africa, where the virus is circulating in a 
sylvatic cycle between forest-dwelling Aedes species mosquitoes and wild primate such as 
chimpanzees, monkeys and baboons (Powers et al., 2000). The first major urban outbreak of 
chikungunya fever was recorded in the early 1960s in Bangkok (Nimmannitya et al., 1969) and 
from 1963-1971 in India (Nimmannitya et al., 1969; Shah, Gibbs Jr and Banerjee, 1964). After 
that, only minor outbreaks occurred occasionally over the next 30 years. However, CHIKV re- 
emerged during 2004 at Kenya and spread throughout countries around the Indian Ocean region, 
Southeast Asia and major epidemic outbreaks at La Reunion a French island from 2005 to 2006 
(Renault et al., 2007). During 2004 to 2007 the outbreaks happened continuously with hundreds 
of thousands of reported cases and novel geographical areas such as Europe (UK, Belgium, 
Germany, Czech Republic, Norway, Italy, Spain and France), Hong Kong, Canada, Taiwan, Sri
6
Lanka and USA (Powers and Logue, 2007). These reported cases in new geographical area 
(Figure 2.3) were directly associated with the return of tourists from India and island of Indian 
Ocean (Warner et al., 2006).
The first CHIKV outbreak in Malaysia was documented during 1998-1999 at Port Klang 
which affected more than 51 persons (Lam et al., 2001) followed by the outbreak in Bagan 
Panchor, Perak (Kumarasamy et al., 2006), and Kinta district, Perak in 2006 (Noridah et al., 
2007). However, the third and largest outbreak was documented in Tangkak, Johor in 2008 
(Apandi et al., 2011).
Geographical Distribution of Chikungunya Virus
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Figure 2.3 Worldwide distribution of CHIKV (Powers and Logue, 2007).
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2.5 Clinical symptoms of CHIKV infection 
The incubation period of CHIK fever is generally 2 - 10 days (Burt et al., 2012; Singh and Unni, 
2011). Some of the seroprevalence studies carried out and showed different rates of 
asymptomatic cases that ranges from 3.8% - 27.7% (Thiberville et al., 2013). According to Win 
et al. (2010), during the acute stages of illness, patients with symptomatic cases typically shows 
the characteristics of high fever, polyarthralgia, headache, back pain and fatigue within 4 - 7 
days of infection. The most distinctive symptom is polyarthralgia which is described in 87% - 
98% of the symptomatic cases (Thiberville et al., 2013). After the acute stages, some of the 
patients' experience recur or consistent symptoms such as arthralgia or musculoskeletal pains 
as a long-lasting sign (Borgherini et al., 2008). Some of the patients infected with CHIKV in 
Reunion island also presented with chronic rheumatic manifestation (Sissoko et al., 2009).
In children the sign of CHIK fever are specific such as hyperpigmentation, generalized 
erythema, maculopapular rash, encephalitis seizures and meningeal syndrome (Robin et al., 
2008). Besides that, vertical transmission of virus from mother to children are observed at the 
outbreak on Reunion island with severe illness observed in 53% of newborns that comprises of 
encephalopathy with persistent disabilities in 44% of newborns (Gerardin et al., 2008).
2.6 Diagnosis of CHIKV infection 
Few methods are used to diagnose CHIKV infection which are through the detection of IgM and 
IgG antibodies through enzyme linked immunosorbent assay (ELISA) and identification 
through viral isolation and viral RNA identification through real-time PCR (RT-PCR), but these 
methods are not carried out widely in hospitals because these methods require special equipment 
and laboratory skills (Okabayashi et al., 2015). The validation of CHIKV isolation may be 
carried out through immunofluorescence or RT-PCR. RT-PCR can deliver a quick and sensitive
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diagnosis, but it is not widely performed in hospitals because it requires specialist equipment 
and laboratory skills (Okabayashi et al., 2015). However, this method is important for early 
diagnosis of CHIKV infection especially newborns with meningoencephalitis and 
vesiculobullous dermatitis (da Cunha and Trinta, 2017). An anti-CHIKV IgM kit is used in 
evaluation of patient with suspected CHIKV (Mourya and Mishra, 2006), but the IgM detection 
kit is only limited to the acute stages of illness (days 1 to 5) (Blacksell et al., 2011). Thus, the 
development of new antigen based diagnostic assay is essential for a fast and reliable clinical 
diagnosis (Okabayashi et al., 2015).
2.7 Treatment of CHIKV 
Currently there are no specific treatment for CHIKV induced disease, and the treatment plans 
involve only supportive and symptomatic care (Goupil and Mores, 2016). The treatment for 
acute stages of infection consists of rest analgescis and antipyretics which includes the 
administration of non-steroidal anti-inflammatory drugs (NSAIDs) and chloroquine in case of 
refractory arthralgia (Simon et al., 2007; Alla and Combe, 2011). NSAIDs are usually used to 
treat inflammation but administration of high doses of NSAIDs can control arthralgia but could 
cause thrombocytopenia, gastrointestinal bleeding, vomiting, gastritis and nausea (Pialoux et al., 
2007).
Some small molecule drugs that target the viral replication are still in experimental stages 
such as ribavirin, chloroquine and Arbidol. Ribavirin shows antiviral activity against a various 
type of RNA virus especially viruses in the genus Alphavirus, such as Semliki forest virus (SFV) 
and CHIKV (Ho, Ng and Chu, 2010). Currently, ribavirin is used in combination with 
interferon- a to treat hepatitis C virus (HPC) infection and respiratory syncytial virus (RSV) 
infections (Crotty, Cameron and Andino, 2002). Next, chloroquine are weak bases that could
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affect acid vesicles and could causes the dysfunction of some enzymes. Some of the virus enter 
their host cell through endocytosis in lysosomal compartment and the low pH disrupts the viral 
particle and releases the viral nucleic acid. Thus, chloroquine can impair the replication of 
viruses by interacting with endosome mediated viral entry (Savarino et al., 2003). The 
application of chloroquine as a treatment for viruses was documented more than 40 years ago 
(Inglot, 1969). However, for alphavirus SFV, the study of Maheshwari, Srikantan and Bhartiya 
(1991), shows that chloroquine enhanced virus replication in mice. Besides, the antiviral drug 
Arbidol (ARB) that has developed by the Center for Drug Chemistry, Moscow is effective 
against respiratory virus such as influenza A and B viruses and respiratory syncytial virus (RSV) 
(Delogu et al., 2011; Brooks et al., 2012). A study also shows that ARB was effective against 
CHIKV in vitro by interfering with the early stages of infection such as the virus attachment and 
entry by targeting the cellular membrane (Delogu et al., 2011).
2.8 Serological test 
Serological test is effective in diagnosing infectious diseases. Through the principle of reaction 
of antigen-antibody, it is used to detect serum antibodies or antigen (Kim, Hwang and Oh, 2016). 
Serology is the detection of increasing titers of antibodies between an acute and convalescent 
stage of infection or detection of IgM in primary infection. There are few serological techniques 
that could be used which includes, ELISA, agglutination, precipitation, complement-fixation, 
fluorescent antibodies or western blot (Martinaskova and Valentova, 2012).
10
3.0 MATERIALS AND METHODS 
3.1 LB medium & agar plate preparation 
Luria Bertani (LB) medium consists of 5 g tryptone (BIO 101, CA, USA), 2.5 g yeast extract 
(amresco, OH, USA), 5 g NaCl (R&M, U. K) are dissolved with R. O water and the volume was 
adjusted to 500 ml. Then the media were autoclaved at 121 °C, 15 psi for 20 minutes (Hirayama, 
Japan). After the LB medium has cooled down, 0.5 ml of 50 µg/ml kanamycin (Appendix A. 1.3) 
were added in biosafety cabinet (Envair, U. K) into the medium and stored at 4 °C until used. 
Then LB agar plate consists of 5 g tryptone (BIO 101, CA, USA), 2.5 g yeast extract (amresco, 
OH, USA), 5 g NaCl (R&M, U. K), 7.5g agar were dissolved with R. 0 water and the volume 
was adjusted to 500 ml. Then the LB agar were autoclaved and 0.5 ml of 50 µg/ml kanamycin 
(Appendix A. 1.3) were added after the agar was cooled down to around 50 °C. After that the LB 
agar was poured into 20 different plates.
3.2 Bacteria culture growth 
The colonies of CHIKV E2 in E. coli labelled with BS1/pE2/Machl/COL1, 
BS I /pE2/Mach 1 /COL, BS 1 /pE2/Mach 1 /COL5, BS 1 /pE2/Mach l /COL6 and 
BS 1 /pE2/Mach 1 /COLT together with the vector DNA colony pET SUMO/Mach 1 /COL4 were 
streaked on Luria Bertani (LB) agar plate containing 50 µg/ml kanamycin in a biosafety cabinet 
(Envair, U. K). The plates were incubated overnight at 37 °C in an incubator (Jisico, Korea).
3.3 Colony polymerase chain reaction (PCR) 
First, colony PCR was done to check the presence of the E2 protein in the colonies. An 
individual colony was picked from plates by using a sterile toothpick and mixed into a 50 pl 
PCR reagent mixture that contain (5 gl lOX Taq buffer, 3 gl 25 mM MgC12, 1.5 µl pE2_F1 
primer (20 pmol/µl), 1.5 gl pET SUMO reverse primer (10 pmol/µl), 1 µl 10 mM dNTP
11
(Fermentas, NY, USA), 0.5 µl Taq polymerase (Fermentas, NY, USA) and 37.5 µl UHQ water). 
The primer sequences used were shown in Table 3.1. For the pET SUMO control, the colony 
was picked and mixed in a 50 gl PCR reagent mixture that contain (5 µl l OX Taq buffer, 3 µl 
25 mM MgC12, 1.5 µl pET SUMO forward primer (10 pmol/µl), 1.5 µl pET SUMO reverse 
primer (10 pmol/µl), 1 µl 10mM dNTP (Fermentas, NY, USA), 0.5 µl Taq polymerase 
(Fermentas, NY, USA), 37.5 pl UHQ water). The PCR was then performed in a thermocycler 
(PTC-200, MJ Research, NY, USA) in the condition shown in Table 3.2. Then, 1.5% agarose 
gel electrophoresis was run at 120 V for 40 minutes (Thermo Scientific, NH, USA) and the 
image was captured (Bio-Rad, CA, USA).
Table 3.1 Primers for colony PCR
Primers Primer sequences 
pET SUMO Forward 5'- AGA TTC TTG TAC GAC GGT ATT AG - 3' 
pET SUMO Reverse 5'- TAG TTA TTG CTC AGC GGT GG - 3'
Table 3.2 Condition for colony PCR reaction
Condition Temperature (°C) Duration Cycles 
Initial denaturation 94 8 minutes I 
Denaturation 94 20 seconds 
Annealing 55 30 seconds 35 
Extension 72 2 minutes 
Final extension 72 5 minutes I
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